KaliDerm Therapeutics: A research/commercialization plan to validate, better define and add value to our proprietary dual KLK5/7 inhibitor as a novel topical therapeutic for Netherton Syndrome.

KaliDerm Therapeutics：一项研究/商业化计划，旨在验证、更好地定义我们专有的双 KLK5/7 抑制剂并为其增加价值，作为 Netherton 综合征的新型局部治疗剂。

• 批准号: 462430
• 负责人: Diamandis Eleftherios P
• 金额: $ 24.52万
• 依托单位: Sinai Health System (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2024-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=462430&lang=en
• 关键词: Crytallography; Dmpk Studies; Drug Development; In Vivo Efficacy Studies; Ind Enabling Studies; Kallikrein Inhibitors; Knowledge Translation; Lead Optimizaiton; Netherton Syndrome; Skin Inflammation

Outer epidermis contains several proteases which collectively orchestrate vital skin functions, such as skin renewal, barrier function and innate immunity. Amongst them, evidence from genetic and biochemical studies have highlighted specifically two prote

外表皮含有几种蛋白水解酶，它们共同协调重要的皮肤功能，如皮肤更新、屏障功能和先天免疫。其中，来自遗传和生化研究的证据特别强调了两个问题